UK markets open in 2 hours 10 minutes

Compass Therapeutics, Inc. (CMPX)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.5000-0.1700 (-3.64%)
At close: 11:21AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.6700
Open4.2500
BidN/A x N/A
AskN/A x N/A
Day's range4.2500 - 4.5000
52-week range4.2500 - 11.0000
Volume208
Avg. volume828
Market cap230.911M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
    Business Wire

    Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

    Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today reported fourth quarter and full year 2020 financial results and provided a business update.

  • Compass Therapeutics Announces Participation in March 2021 Investor Conferences
    Business Wire

    Compass Therapeutics Announces Participation in March 2021 Investor Conferences

    Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer of Compass Therapeutics, will participate in the following virtual investor conferences:

  • Compass Therapeutics to Commence Trading on the OTCQB Venture Market Under the Symbol "CMPX"
    Business Wire

    Compass Therapeutics to Commence Trading on the OTCQB Venture Market Under the Symbol "CMPX"

    Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, announced today that shares of the company’s common stock have been cleared for trading on the OTCQB Venture Market in the United States. The Company’s shares will trade under the ticker symbol "CMPX", effective at the market open on March 5, 2021.